Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

NCT00179699 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: CC-5013
DRUG: pemetrexed

Sponsor

Celgene Corporation

Collaborators

[object Object]